WO2004108763A3 - Mutants of the factor vii epidermal growth factor domain - Google Patents
Mutants of the factor vii epidermal growth factor domain Download PDFInfo
- Publication number
- WO2004108763A3 WO2004108763A3 PCT/CA2004/000826 CA2004000826W WO2004108763A3 WO 2004108763 A3 WO2004108763 A3 WO 2004108763A3 CA 2004000826 W CA2004000826 W CA 2004000826W WO 2004108763 A3 WO2004108763 A3 WO 2004108763A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mutants
- domain
- epidermal growth
- factor
- growth factor
- Prior art date
Links
- 102000009024 Epidermal Growth Factor Human genes 0.000 title 1
- 101800003838 Epidermal growth factor Proteins 0.000 title 1
- 229940116977 epidermal growth factor Drugs 0.000 title 1
- 229940012413 factor vii Drugs 0.000 title 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title 1
- 230000035772 mutation Effects 0.000 abstract 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
- 238000002965 ELISA Methods 0.000 abstract 1
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 abstract 1
- 230000003024 amidolytic effect Effects 0.000 abstract 1
- 239000003114 blood coagulation factor Substances 0.000 abstract 1
- 229940019700 blood coagulation factors Drugs 0.000 abstract 1
- 230000035602 clotting Effects 0.000 abstract 1
- 230000002860 competitive effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000012163 sequencing technique Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The application relates to modified blood coagulation factor, sequencing encoding such modified factors, processes for their production, and related pharmaceutical compositions comprising such factors and their uses. More specifically, the application relates to mutations in the human FVII EGF-1 domain, wherein said mutations were analyzed for clotting activity, amidolytic activity and affinity of binding to full-length, relipidated human TF by competitive ELISA.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002528239A CA2528239A1 (en) | 2003-06-05 | 2004-06-03 | Mutants of the factor vii epidermal growth factor domain |
| EP04735858A EP1636358A2 (en) | 2003-06-05 | 2004-06-03 | Mutants of the factor vii epidermal growth factor domain |
| US11/294,670 US20060234935A1 (en) | 2003-06-05 | 2005-12-05 | Mutants of the factor VII epidermal growth factor domain |
| US11/636,030 US20070207960A1 (en) | 2003-06-05 | 2006-12-08 | Mutants of the factor VII epidermal growth factor domain |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47590503P | 2003-06-05 | 2003-06-05 | |
| US60/475,905 | 2003-06-05 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/294,670 Continuation US20060234935A1 (en) | 2003-06-05 | 2005-12-05 | Mutants of the factor VII epidermal growth factor domain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004108763A2 WO2004108763A2 (en) | 2004-12-16 |
| WO2004108763A3 true WO2004108763A3 (en) | 2005-02-17 |
Family
ID=33511728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA2004/000826 WO2004108763A2 (en) | 2003-06-05 | 2004-06-03 | Mutants of the factor vii epidermal growth factor domain |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20060234935A1 (en) |
| EP (1) | EP1636358A2 (en) |
| CA (1) | CA2528239A1 (en) |
| WO (1) | WO2004108763A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9476037B2 (en) | 2008-04-11 | 2016-10-25 | Catalyst Biosciences, Inc. | Factor VII polypeptides that are modified and uses thereof |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0514396A2 (en) | 2004-08-17 | 2009-05-12 | Csl Behring Gmbh | modified vitamin K dependent polypeptides |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| ES2397851T3 (en) | 2005-07-13 | 2013-03-11 | Novo Nordisk Health Care Ag | Host cell protein inactivation cells for the production of therapeutic proteins |
| ES2515915T3 (en) | 2005-09-01 | 2014-10-30 | Novo Nordisk Health Care Ag | Purification of Factor VII polypeptides by hydrophobic interaction chromatography |
| WO2007031559A2 (en) | 2005-09-14 | 2007-03-22 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
| JP5570809B2 (en) | 2006-09-01 | 2014-08-13 | ノボ ノルディスク ヘルス ケア アーゲー | Modified protein |
| NZ579985A (en) | 2007-04-13 | 2012-02-24 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof |
| JP5909180B2 (en) * | 2009-06-25 | 2016-04-26 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Chimeric factor VII molecule |
| CN104211799B (en) * | 2013-05-29 | 2017-12-26 | 成都渊源生物科技有限公司 | Human Epidermal growth factor domain protein and its application |
| CN104211802B (en) * | 2013-05-29 | 2018-07-27 | 成都渊源生物科技有限公司 | Human blood coagulation light chain protein and its application |
| EP3833381B1 (en) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration |
| CN116143929B (en) * | 2023-02-03 | 2023-08-01 | 北京基科晟斯医药科技有限公司 | Antibody against recombinant human coagulation factor VIIa-Fc fusion protein and application thereof |
-
2004
- 2004-06-03 CA CA002528239A patent/CA2528239A1/en not_active Abandoned
- 2004-06-03 WO PCT/CA2004/000826 patent/WO2004108763A2/en active Search and Examination
- 2004-06-03 EP EP04735858A patent/EP1636358A2/en not_active Withdrawn
-
2005
- 2005-12-05 US US11/294,670 patent/US20060234935A1/en not_active Abandoned
Non-Patent Citations (7)
| Title |
|---|
| BROTHERS ALEX B ET AL: "Complete nucleotide sequence of the cDNA encoding rabbit coagulation factor VII", THROMBOSIS RESEARCH, vol. 69, no. 2, 1993, pages 231 - 238, XP009041224, ISSN: 0049-3848 * |
| CLARKE B.: "Interspecies exchange mutagenesis of the first growth factor-like domain of human factor VII", J. THROMBOSIS AND HAEMOSTASIS, vol. 1, 2003, SUPPLEMENT 1 JULY, pages ABSTRACT NUMBER P0559, XP001204193 * |
| DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 1998 (1998-06-01), KAVLIE ANITA ET AL: "Characterization of a factor VII molecule carrying a mutation in the second epidermal growth factor-like domain", XP002309720, Database accession no. PREV199800347106 * |
| KAZAMA Y ET AL: "Evidence that an Arg-79 fwdarw Gln substitution in human factor VII is not associated with a reduction in coagulant activity", BLOOD COAGULATION AND FIBRINOLYSIS, vol. 3, no. 6, 1992, pages 697 - 702, XP009041242, ISSN: 0957-5235 * |
| PERSSON E ET AL: "Ca2+ in the first epidermal growth factor-like domain of activated factor VII", BLOOD COAGULATION AND FIBRINOLYSIS, vol. 9, no. SUPPL. 1, March 1998 (1998-03-01), & 4TH SYMPOSIUM ON NEW ASPECTS OF HAEMOPHILIA TREATMENT; COPENHAGEN, DENMARK; SEPTEMBER 19-20, 1997, pages S79 - S81, XP009041243, ISSN: 0957-5235 * |
| SRIDHARA SAMPATH ET AL: "Activation of a recombinant human factor VII structural analogue alters its affinity of binding to tissue factor", AMERICAN JOURNAL OF HEMATOLOGY, vol. 53, no. 2, 1996, pages 66 - 71, XP009041225, ISSN: 0361-8609 * |
| THROMBOSIS AND HAEMOSTASIS, vol. 79, no. 6, June 1998 (1998-06-01), pages 1136 - 1143, ISSN: 0340-6245 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9476037B2 (en) | 2008-04-11 | 2016-10-25 | Catalyst Biosciences, Inc. | Factor VII polypeptides that are modified and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1636358A2 (en) | 2006-03-22 |
| CA2528239A1 (en) | 2004-12-16 |
| US20060234935A1 (en) | 2006-10-19 |
| WO2004108763A2 (en) | 2004-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004108763A3 (en) | Mutants of the factor vii epidermal growth factor domain | |
| WO2005063820A3 (en) | Il-7 fusion proteins | |
| ATE493148T1 (en) | ANTIBODIES FOR INHIBITING BLOOD CLOTTING AND METHOD OF USE THEREOF | |
| WO2008028686A3 (en) | Use of human cells of myeloid leukaemia origin for expression of antibodies | |
| WO2001092308A3 (en) | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof | |
| JO2828B1 (en) | Anti-Hepcidin Antibodies and Uses Thereof | |
| WO2007092640A3 (en) | Antibodies that bind par-2 | |
| ATE410178T1 (en) | OLIGOPEPTIDES TO REDUCE INCREASED BLOOD UREA CONCENTRATION | |
| SG161247A1 (en) | Variant forms of urate oxidase and use thereof | |
| WO2006114105A3 (en) | Use of modified factor vii for treating bleeding | |
| PL1969127T5 (en) | Method of producing biologically active vitamin k dependent proteins by recombinant methods | |
| WO2008008482A3 (en) | Altered br3-binding polypeptides | |
| WO2005056585A3 (en) | Sars coronavirus s proteins and uses thereof | |
| IL168435A (en) | Composition comprising recombinant precursor human n-acetylgalactosamine-4-sulfatase, uses thereof and methods for producing and purifying said enzyme | |
| WO2007060213A3 (en) | Erythropoietin polypeptides and uses thereof | |
| Gundberg et al. | Vitamin K dependent proteins of bone and cartilage | |
| WO2003097810A3 (en) | Nitrilases, nucleic acids encoding them and methods for making and using them | |
| TW200734638A (en) | Method for the diagnosis of thromboembolic and coronary heart diseases | |
| WO2004094476A3 (en) | Compositions and methods relating to stop-1 | |
| WO2004081229A3 (en) | Use of bv8 and/or eg-vegf to promote hematopoiesis | |
| WO2005018552A3 (en) | Heparin binding proteins: sensors for heparin detection | |
| Kim et al. | Existence of stable fibrin-clotting inhibitor in salt-fermented anchovy sauce | |
| WO2007143578A3 (en) | Perforin-2 proteins | |
| WO2003050134A3 (en) | Crystalline neutrokine-alpha protein, method of preparation thereof, and method of use thereof | |
| ATE540967T1 (en) | METHOD FOR PURIFYING PROTEINS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2528239 Country of ref document: CA Ref document number: 11294670 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004735858 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004735858 Country of ref document: EP |
|
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| WWP | Wipo information: published in national office |
Ref document number: 11294670 Country of ref document: US |